It seems we can’t find what you’re looking for. Perhaps searching can help.
1933 - 2018
A Phase 3, Randomized, Double-blind Study of Pembrolizumab Odette Cancer Centre – (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)